Efficacy and safety of twice-daily glycopyrrolate in patients with stable , symptomatic COPD with moderate-to-severe airflow limitation : the GEM 1 study

and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). International Journal of COPD 2016:11 1233–1243 International Journal of COPD Dovepress